NEW YORK (GenomeWeb News) - Perlegen Sciences said this week that it has licensed certain breast cancer biomarkers from Cambridge Enterprise Limited, the commercial arm of Cambridge University, and plans to commercialize the markers as a diagnostic test.
 
The agreement stems from a large-scale breast cancer study Perlegen, Cambridge, and Cancer Research UK began in 2005 that genotyped more than 50,000 women.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.